Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas, F
Miranda Rota, E
Ben Aissa, A
Werner Sunderland, M
Melanoma TRACERx Consortium
Renal TRACERx Consortium
Lung TRACERx Consortium
MetadataShow full item record
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models. Use of an anti-CD25 antibody with enhanced binding to activating FcγRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies promoted complete tumor rejection, demonstrating the relevance of CD25 as a therapeutic target and promising substrate for future combination approaches in immune-oncology.
Version of record
Fc gamma receptors
inhibitory Fc receptor
regulatory T cells
Cell Line, Tumor
Immunoglobulin Fc Fragments
Interleukin-2 Receptor alpha Subunit
Programmed Cell Death 1 Receptor
Melanoma and Kidney Cancer
License start date
Immunity, 2017, 46 (4), pp. 577 - 586
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Wong, JP; Todd, JR; Finetti, MA; McCarthy, F; Broncel, M; Vyse, S; Luczynski, MT; Crosier, S; Ryall, KA; Holmes, K; Payne, LS; Daley, F; Wai, P; Jenks, A; Tanos, B; Tan, A-C; Natrajan, RC; Williamson, D; Huang, PH (2016-10-25)Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF ...
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial. Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; Dowsett, M (2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen ...
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Di Leo, A; Johnston, S; Lee, KS; Ciruelos, E; Lønning, PE; Janni, W; O'Regan, R; Mouret-Reynier, M-A; Kalev, D; Egle, D; Csőszi, T; Bordonaro, R; Decker, T; Tjan-Heijnen, VCG; Blau, S; Schirone, A; Weber, D; El-Hashimy, M; Dharan, B; Sellami, D; Bachelot, T (2018-01)BACKGROUND: Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT ...